Current evidence on the use of anakinra in COVID-19 - ScienceDirect
Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study | Clinical Rheumatology
Cancers | Free Full-Text | Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity
Kineret, INN-anakinra
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society for ...
2019 Clinical Guidelines Template
Kineret Subcutaneous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
Frontiers | Anakinra Therapy for Non-cancer Inflammatory Diseases
Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis - ScienceDirect
Study Backs Cytokine Targeting for COVID-19 Tx | MedPage Today
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society for ...
Frontiers | Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
Frontiers | Anakinra Pilot – a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants
Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome | The Journal of Rheumatology
AusPAR Attachment 2: Extract from the Clinical Evaluation Report for Anakinra
The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis - Bami - 2020 - Pediatric Blood & Cancer - Wiley Online Library
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results | Nature Medicine
KINERET® (anakinra) Official Website | Using KINERET for NOMID
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance - Sofia Ajeganova, Ann De Becker, Rik Schots, 2020
Anakinra reduces ventilation need, mortality in COVID-19
IJMS | Free Full-Text | Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy
Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes | BMC Pharmacology and Toxicology | Full Text
Arthritis News: Study Finds No Treatment Benefit of Intra-Articular Anakinra in Knee Osteoarthritis
PulmCrit – High-dose anakinra for COVID-19: The anti-inflammatory trials begin
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry | The Journal of Rheumatology
Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study | Clinical Rheumatology
Anakinra for Gout Flares: Is There a Role? | MedPage Today
